Search research articles
Contact Us
Filters
Showing results (11-20 of 72) with videos related to
Page
of 8
Sort By:
Ophthalmology
|
August 1, 2006
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration
Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, et al.
Contemporary Clinical Trials
|
December 26, 2021
Considerations to address missing data when deriving clinical trial endpoints from digital health technologies
Junrui Di, Charmaine Demanuele, Anna Kettermann, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 1, 2025
Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples
YuTing Liu, Minhua Yang, Kyle Fraser, et al.
Journal of the Neurological Sciences
|
August 3, 2020
Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches
Amgad Droby, Nurit Omer, Tanya Gurevich, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 27, 2024
<b>Quantification</b> <b>of</b> <b>Cinpanemab (BIIB054) Binding to</b> <b>α-</b> <b>Synuclein in Cerebrospinal Fluid of Phase 1 Single Ascending Dose Samples</b>
YuTing Liu, Minhua Yang, Kyle Fraser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Raina Vin, Hae Young H Yi, Sophia Moret, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 27, 2022
Application of longitudinal item response theory models to modeling Parkinson's disease progression
Haotian Zou, Varun Aggarwal, Glenn T Stebbins, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects
Earvin Liang, Pamela Garzone, Jesse M Cedarbaum, et al.
BMC Neurology
|
November 24, 2021
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial
R Matthew Hutchison, Karleyton C Evans, Tara Fox, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 4, 2025
Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder
Vijaya L Reddy, Samantha Esposito, Erika Renkl, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 72) with videos related to
Sort By:
Page
of 8
Ophthalmology
|
August 1, 2006
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration
Quan Dong Nguyen, Syed Mahmood Shah, Gulnar Hafiz, et al.
Contemporary Clinical Trials
|
December 26, 2021
Considerations to address missing data when deriving clinical trial endpoints from digital health technologies
Junrui Di, Charmaine Demanuele, Anna Kettermann, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
February 1, 2025
Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples
YuTing Liu, Minhua Yang, Kyle Fraser, et al.
Journal of the Neurological Sciences
|
August 3, 2020
Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches
Amgad Droby, Nurit Omer, Tanya Gurevich, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 27, 2024
<b>Quantification</b> <b>of</b> <b>Cinpanemab (BIIB054) Binding to</b> <b>α-</b> <b>Synuclein in Cerebrospinal Fluid of Phase 1 Single Ascending Dose Samples</b>
YuTing Liu, Minhua Yang, Kyle Fraser, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 24, 2025
Biomarkers
Raina Vin, Hae Young H Yi, Sophia Moret, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 27, 2022
Application of longitudinal item response theory models to modeling Parkinson's disease progression
Haotian Zou, Varun Aggarwal, Glenn T Stebbins, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects
Earvin Liang, Pamela Garzone, Jesse M Cedarbaum, et al.
BMC Neurology
|
November 24, 2021
Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial
R Matthew Hutchison, Karleyton C Evans, Tara Fox, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 4, 2025
Characterizing Parkinson's Disease Clinical and Biomarker Interactions in REM Sleep Behavior Disorder
Vijaya L Reddy, Samantha Esposito, Erika Renkl, et al.
Page
of 8